1. Generics Bulletin

Alvotech And Jamp Launch First Stelara Biosimilar In Canada

Jamteki Version Of Ustekinumab Introduced By Jamp Is Country’s First Stelara Rival

 
• By Dave Wallace

Alvotech and Jamp have launched Canada’s first Stelara biosimilar, just a couple of weeks after Alvotech disclosed a settlement that would allow its ustekinumab product to be introduced in markets around the world.

Man with flag of Canada, leadership
Jamp and Alvotech have launched ustekinumab in Canada • Source: Shutterstock

Canada’s first Stelara (ustekinumab) biosimilar has been introduced to the market by Alvotech and marketing partner Jamp Pharma through the latter’s BioJamp unit. The launch comes after the firms received approval from Health Canada towards the end of 2023. (Also see "Alvotech Notches Up Another Stelara Biosimilar Approval – In Canada" - Generics Bulletin, 14 November, 2023.).

The first ustekinumab biosimilar to receive a marketing authorization in Canada, the pair’s Jamteki version has been launched just a couple of weeks after Alvotech disclosed a wide-ranging settlement agreement with Stelara originator Johnson & Johnson that would

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.